Avid Bioservices, Inc.

Equities

CDMO

US05368M1062

Pharmaceuticals

Delayed Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
6.7 USD -4.01% Intraday chart for Avid Bioservices, Inc. -2.47% +3.08%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
North American Morning Briefing : Stocks Struggle After New Records DJ
Avid Bioservices Receives Nasdaq Noncompliance Notice MT
North American Morning Briefing : Inflation Worries Continue to Weigh on Mood DJ
Stephens Adjusts Price Target on Avid Bioservices to $12 From $15, Maintains Overweight Rating MT
Avid Bioservices Prices $160 Million Convertible Notes Offering; Shares Slump MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Buoyed by Powell's Comments MT
Top Premarket Decliners MT
Avid Bioservices Shares Slide After Pricing Private Placement of Convertible Notes DJ
Avid Bioservices Prices $160 Million Convertible Notes Offering MT
Avid Bioservices Preliminary Fiscal Q3 Revenue Falls 11%; $160 Million Private Placement of Notes Set; Shares Slump MT
Avid Bioservices, Inc. Maintains Revenue Guidance for Full Fiscal Year 2024 CI
Avid Bioservices, Inc. announced that it expects to receive $160 million in funding CI
In moon race with China, U.S. setbacks test role of private firms RE
Avid Bioservices, Inc.(NasdaqCM:CDMO) dropped from S&P 1000 CI
Avid Bioservices, Inc.(NasdaqCM:CDMO) dropped from S&P 600 Health Care CI
Avid Bioservices, Inc.(NasdaqCM:CDMO) dropped from S&P Composite 1500 CI
Avid Bioservices, Inc.(NasdaqCM:CDMO) dropped from S&P 600 CI
Craig-Hallum Adjusts Avid Bioservices' Price Target to $16 From $22, Maintains Buy Rating MT
Avid Bioservices Faces Uphill Battle as Overall Demand Environment Poses Challenges, RBC Says MT
KeyBanc Cuts Price Target on Avid Bioservices to $14 From $20, Maintains Overweight Rating MT
Sector Update: Health Care Stocks Lean Lower Premarket Friday MT
November Payrolls Post Bigger Gain Than Expected as Exchange-Traded Funds, Equity Futures Slide Pre-Bell MT
Sector Update: Health Care MT
RBC Cuts Price Target on Avid Bioservices to $7 From $15, Cites Slower Revenue Growth Assumptions Amid 'Challenging' Demand Backdrop; Outperform Kept MT
Avid Bioservices Fiscal Q2 Loss Widens, Revenue Falls; Cuts Fiscal 2024 Sales Outlook; Shares Plunge Premarket MT
Chart Avid Bioservices, Inc.
More charts
Avid Bioservices, Inc. is a contract development and manufacturing organization (CDMO). The Company provides a range of services from process development to Current Good Manufacturing Practices (CGMP) clinical and commercial manufacturing of biologics for the biotechnology and biopharmaceutical industries. It operates in a single segment, which is contract manufacturing and development services. The Company’s services include clinical and commercial product manufacturing, bulk packaging, release and stability testing and regulatory submissions support. The Company also provides a variety of process development services, including upstream and downstream development and optimization, analytical methods development, testing and characterization. It provides fully integrated and customized biomanufacturing services that support its customers from the early preclinical stage to commercial launch and supply.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
6.7 USD
Average target price
12.25 USD
Spread / Average Target
+82.84%
Consensus
  1. Stock
  2. Equities
  3. Stock Avid Bioservices, Inc. - Nasdaq
  4. News Avid Bioservices, Inc.
  5. Sector Update: Health Care Stocks, Like Broader Tuesday Markets, Struggling for Direction